Drug Combination Details
| General Information of the Combination (ID: C48781) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Nilotinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BTG1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TAL1 | Molecule Info | |||
| In-vitro Model | Cells derived from the bone marrow of CML-BC patients | Chronic Myelogenous Leukemia | Homo sapiens | |||
| Experimental
Result(s) |
ATO and nilotinib treatment alone or in combination greatly suppressed cell proliferation but promoted the differentiation of CML-BC cells towards multiple-lineages. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
ATO synergistically potentiated the apoptotic efficacy of the TKI AMN107 in imatinib-resistant CML cell. | |||||
